Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
Myriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Yahoo Finance9d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research ...
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Nasdaq9d
Myriad Genetics Breaks New Ground With Early Prenatal Testing At Eight Weeks
(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic testing and precision medicine company, on Wednesday announced its groundbreaking study results on the Prequel Prenatal Screen with AMPLIFY ...